

## Disclosures

### Personal Commercial (15)

| Company Name                              | Relationship Category     | Compensation Level       | Topic Area(s)                     |
|---|---------------------------|--------------------------|-----------------------------------|
| <i>Self</i>                               |                           |                          |                                   |
| Amgen Inc.                                | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| Arrowhead                                 | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| AstraZeneca Pharmaceuticals               | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| Bayer Healthcare Pharmaceuticals          | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention                        |
| Edwards Lifesciences                      | Consultant Fees/Honoraria | Modest (< \$5,000)       | Valvular Heart Disease            |
| Eli Lilly and Company                     | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| Esperion                                  | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention                        |
| Ionis                                     | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| Medtronic                                 | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention Valvular Heart Disease |
| Merck & Co., Inc.                         | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention                        |
| New Amsterdam                             | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| Novartis Corporation                      | Consultant Fees/Honoraria | Modest (< \$5,000)       | Prevention                        |
| Novo Nordisk Inc.                         | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention                        |
| Zoll                                      | Consultant Fees/Honoraria | Modest (< \$5,000)       | Other                             |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (4)

| Non-Commercial Entity Name                          | Relationship Category                | Compensation Level       | Topic Area(s)                 |
|---|--------------------------------------|--------------------------|-------------------------------|
| <i>Self</i>   |                                      |                          |                               |
| American Heart Association<br>† none                | Research/Research Grants             | Significant (>= \$5,000) | Prevention                    |
| American Journal of Preventive Cardiology<br>† none | Other - Editor in Chief of a journal | Significant (>= \$5,000) | Prevention                    |
| National Institutes of Health                       | Research/Research Grants             | Significant (>= \$5,000) | Prevention General Cardiology |
| National Institutes of Health                       | Research/Research Grants             | Significant (>= \$5,000) | Other                         |

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 4/21/2025  
*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 4/21/2025  
*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 4/21/2025  
*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 4/21/2025

---

**ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.